Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Medical Societies Issue Joint Statement in Face of Possible Stockout of Abraxane, Calling for Continued Treatment
Taiho Pharmaceutical said on August 26 in a statement addressed to patients and their families that its anticancer agent Abraxane IV Infusion 100 mg (paclitaxel) is likely to face a stockout around the middle of October. In response, medical societies…
To read the full story
Related Article
- Taiho Lifts Shipment Control on Abraxane
June 21, 2022
- Abraxane Supply Secured until around July: Taiho
January 26, 2022
- Abraxane Supply to Continue until Mid-December without Possible Stockouts: Taiho
October 13, 2021
BUSINESS
- Hisamitsu Sets April 17 Shareholders Meeting to Approve Squeeze-Out
March 16, 2026
- AbbVie Japan Files Rinvoq for Vitiligo
March 16, 2026
- SSP Appoints Yoko Motoshima as New President
March 16, 2026
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…